Vivani Medical's preclinical data for semaglutide implant shows promising weight loss results

From StockTwits: 2025-03-26 20:52:00

Vivani Medical, Inc. announced positive preclinical data for its semaglutide implant, showing a 20% lower body weight in healthy rats compared to a control group. CEO Adam Mendelsohn highlighted the potential of a more convenient delivery option for weight-loss drugs containing semaglutide, which generated $25 billion in 2024. The company is developing NPM-139 as a twice-yearly implant with potential for once-yearly administration. Retail sentiment on Stocktwits shifted from ‘bullish’ to ‘extremely bullish,’ with message volume increasing. Brokerage H.C. Wainwright reiterated a ‘Buy’ rating on VANI shares with a price target of $4, praising the NanoPortal implant technology. VANI shares traded nearly 2% higher on Wednesday.



Read more at StockTwits: Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars